Evaluation of Co-formulated Pembrolizumab/Quavonlimab Versus Other Treatments in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer

Trial purpose

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

View full trial information on Clinicaltrials.gov

	national trial reference number	NCT04895722
	Conditions	Colorectal Cancer
	Age Range	18+
	Sex	All
	Current trial phase	2
	Trial start and end dates	06-25-2021 06-30-2027

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT04895722

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.